Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective This study was performed to evaluate the efficacy and safety of lurasidone (160 mg/day) compared to quetiapine XR (QXR; 600 mg/day) in the treatment of acutely psychotic patients with schizophrenia. Methods Patients were randomly assigned to 6 weeks of double-blind treatment with lurasidone 160 mg/day (n=105) or QXR 600 mg/ day (n=105). Primary efficacy measure was the change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions severity (CGI-S) score. Adverse events, body measurements, and laboratory parameters were assessed. Results Lurasidone demonstrated non-inferiority to QXR on the PANSS total score. Adjusted mean±standard error change at week 6 on the PANSS total score was -26.42±2.02 and -27.33±2.01 in the lurasidone and QXR group, respectively. The mean difference score was -0.91 (95% confidence interval -6.35–4.53). The lurasidone group showed a greater reduction in PANSS total and negative subscale on week 1 and a greater reduction in end-point CGI-S score compared to the QXR group. Body weight, body mass index, and waist circumference in the lurasidone group were reduced, with significantly lower mean change compared to QXR. Endpoint changes in glucose, cholesterol, triglycerides, and low-density lipoprotein levels were also significantly lower. The most common adverse drug reactions with lurasidone were akathisia and nausea. Conclusion Lurasidone 160 mg/day was found to be non-inferior to QXR 600 mg/day in the treatment of schizophrenia with comparable efficacy and tolerability. Adverse effects of lurasidone were generally tolerable, and beneficial effects on metabolic parameters can be expected.
Abstract
Objective This study was performed to evaluate the efficacy and safety of lurasidone (160 mg/day) compared to quetiapine XR (QXR; 600 mg/day) in the treatment of acutely psychotic patients with schizophrenia. Methods Patients were randomly assigned to 6 weeks of double-blind treatment with lurasidone 160 mg/day (n=105) or QXR 600 mg/ day (n=105). Primary efficacy measure was the change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions severity (CGI-S) score. Adverse events, body measurements, and laboratory parameters were assessed. Results Lurasidone demonstrated non-inferiority to QXR on the PANSS total score. Adjusted mean±standard error change at week 6 on the PANSS total score was -26.42±2.02 and -27.33±2.01 in the lurasidone and QXR group, respectively. The mean difference score was -0.91 (95% confidence interval -6.35–4.53). The lurasidone group showed a greater reduction in PANSS total and negative subscale on week 1 and a greater reduction in end-point CGI-S score compared to the QXR group. Body weight, body mass index, and waist circumference in the lurasidone group were reduced, with significantly lower mean change compared to QXR. Endpoint changes in glucose, cholesterol, triglycerides, and low-density lipoprotein levels were also significantly lower. The most common adverse drug reactions with lurasidone were akathisia and nausea. Conclusion Lurasidone 160 mg/day was found to be non-inferior to QXR 600 mg/day in the treatment of schizophrenia with comparable efficacy and tolerability. Adverse effects of lurasidone were generally tolerable, and beneficial effects on metabolic parameters can be expected.
참고문헌 (41)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Miyamoto S, "Pharmacological treatment of schizophrenia : a critical review of the pharmacology and clinical effects of current and future therapeutic agents", Mol Psychiatry, 17, pp.1206~1227 (2012)
- Pompili M, "Lurasidone : efficacy and safety in the treatment of psychotic and mood disorders", Expert Opin Drug Saf, 17, pp.197~205 (2018)
- Murai T, "Lack of do pamine D4 receptor affinity contributes to the procognitive effect of lurasidone", Behav Brain Res, 261, pp.26~30 (2014)
- Ishibashi T, "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7(5-HT7)and 5-HT1A receptor ac tivity", J Pharmacol Exp Ther, 334, pp.171~181 (2010)
- Weiden PJ, "EPS profiles : the atypical antipsychotics : are not all the same", J Psychiatr Pract, 13, pp.13~24 (2007)
- Shimizu S, "Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.877881~ (2010)
- Potkin SG, "D2 receptor occupancy following lurasidone treat ment in patients with schizophrenia or schizoaffective disorder", CNS Spectr, 19, pp.176~181 (2014)
- Calisti F, "Efficacy and safety of lurasidone in schizophrenia : pooled analysis of European results from double-blind, placebo-controlled 6-week stud ies", Int Clin Psychopharmacol, 37, pp.215~222 (2022)
- Higuchi T, "Lurasidone in the treatment of schizophrenia : results of a double-blind, placebo-controlled trial in Asian patients", Asia Pac Psychiatry, 11, pp.e12352~ (2019)
- Higuchi T, "Ran domized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia : results of an inconclusive 6-week trial", Asia Pac Psychiatry, 11, pp.e12354~ (2019)
- Iyo M, "Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia : a 6-week, randomized, double-blind, placebo-con trolled study", Psychiatry Clin Neurosci, 75, pp.227~235 (2021)
- Bruijnzeel D, "Lurasidone in the treatment of schizophrenia : a critical evaluation", Expert Opin Pharmacother, 16, pp.1559~1565 (2015)
- Bawa R, "Lurasidone : a new treatment option for bipolar de pression-a review", Innov Clin Neurosci, 12, pp.21~23 (2015)
- Miura I, "Lurasidone for the treatment of schizophrenia : design, development, and place in therapy", Drug Des Devel Ther, 17, pp.3023~3031 (2023)
- Tarzian M, "Lurasidone for treating schizophrenia and bipolar depression : a review of its efficacy", Cureus, 15, pp.e38071~ (2023)
- Guilera T, "Lurasidone for the treatment of schizophrenia in adult and paediatric populations", Drugs Context, 12, pp.2022~2010 (2023)
- Zheng W, "Short-term efficacy and tolerability of lurasidone in the treatment of acute schizo phrenia : a meta-analysis of randomized controlled trials", J Psychiatr Res, 103, pp.244~251 (2018)
- De Hert M, "Body weight and metabolic adverse effects of asenapine, iloperidone, lurasi done and paliperidone in the treatment of schizophrenia and bipolar disorder : a systematic review and exploratory meta-analysis", CNS Drugs, 26, pp.733~759 (2012)
- Busner J, "The clinical global impressions scale : applying a research tool in clinical practice", Psychiatry(Edgmont), 4, pp.28~37 (2007)
- Kay SR, "The positive and negative syndrome scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Yi JS, "Reliability and validity of the Korean version of the positive and negative syndrome scale", J Korean Neuropsychiatr Assoc, 40, pp.1090~1105 (2001)
- Peljto A, "Drug-induced extrapyramidal symptoms scale(DIEPSS)Serbian language version : inter-rater and test-retest reliability", Sci Rep, 7, pp.8105~ (2017)
- Kim JH, "Metric characteristics of the drug-induced extrapyramidal symptoms scale(DIEPSS) : a practical combined rating scale for drug-induced move ment disorders", Mov Disord, 17, pp.1354~1359 (2002)
- Posner K, "The Columbia-suicide severity rating scale : initial validity and in ternal consistency findings from three multisite studies with adoles cents and adults", Am J Psychiatry, 168, pp.1266~1277 (2011)
- Posner K, "Co lumbia-suicide severity rating scale(C-SSRS)" (2008), New York State Psychiatric Institute
- "Reviewing and report ing unanticipated problems involving risks to subjects or others and ad verse events: OHRP guidance (2007)"[URL]
- "NIA Adverse Event and Serious Adverse Event Guidelines, version 5"[URL]
- Loebel A, "Efficacy and safety of lurasidone 80 mg", day and 160 mg, Schizophr Res, pp.2013, 145[DOI]
- Carbon M, "Clinical predictors of therapeutic response to antipsychotics in schizophrenia", Dialogues Clin Neurosci, 16, pp.505524~ (2014)
- Kinon BJ, "Early response to antipsychotic drug therapy as a clini cal marker of subsequent response in the treatment of schizophrenia", Neuropsychopharmacology, 35, pp.581~590 (2010)
- Kishi T, "Early improvement as a predictor of later response to lurasidone in schizophrenia from Japan trials : a diag nostic test", Psychiatry Clin Neurosci, 76, pp.401~402 (2022)
- Nakamura M, "Lurasidone in the treatment of acute schizophrenia : a double-blind, placebo-controlled trial", J Clin Psychiatry, 70, pp.829~836 (2009)
- Citrome L, "Lurasidone for schizophrenia : a review of the efficacy and safety profile for this newly approved second-generation antipsychotic", Int J Clin Pract, 65, pp.189~210 (2011)
- Jaeschke RR, "Lurasidone : the 2016 update on the pharmacolo gy, efficacy and safety profile", Pharmacol Rep, 68, pp.748~755 (2016)
- Samalin L, "Clinical potential of lurasidone in the management of schizophrenia", Ther Clin Risk Manag, 7, pp.239250~ (2011)
- Nakamura M, "Impact of lurasidone on metabolic param eters and prolactin levels based on differences of psychiatric diagnosis, dosage, and introducing methods : an observational study", Innov Clin Neurosci, 19, pp.70~77 (2022)
- Nagamine T, "Mild decrease in blood glucose levels may predict efficacy of antipsychotic lurasidone", Clin Psychopharmacol Neurosci, 21, pp.207~209 (2023)
- Reynolds GP, "Adjunctive lurasidone suppresses food intake and weight gain associated with olanzapine administration in rats", Clin Psychopharmacol Neurosci, 17, pp.314~317 (2019)
- Haddad PM, "Antipsychotic-related QTc prolongation, torsade de pointes and sudden death", Drugs, 62, pp.1649~1671 (2002)
- Straus SM, "Prolonged QTc interval and risk of sudden cardiac death in a population of older adults", J Am Coll Cardiol, 47, pp.362~367 (2006)